Germline genetic testing for prostate cancer has increased, especially after the 2018 NCCN guideline expansion. Urologists are ordering more tests, particularly for younger patients and those without ...

"We were trying to understand how veterans were making decisions about germline testing for their prostate cancer," says Daniel Kwon, MD. In this video, Daniel Kwon, MD, discusses the background and ...

The combination therapy showed a 42.1% pathological complete response rate, similar to cisplatin-based chemotherapy, with no dose-limiting toxicities observed. Grade 3 or higher treatment-emergent ...

Leslie M. Rickey is the first woman in Yale's Department of Urology to achieve full professor status, highlighting her expertise in female pelvic medicine and urogynecology. Women face significant ...

High prevalence of VUS in prostate cancer patients undergoing RARP, potentially affecting pathological outcomes. Younger patients more likely to carry VUS, with 23.7% of study participants affected.

AI is revolutionizing urology, enhancing imaging, pathology, and endoscopy, with potential for AI-guided procedures like cystoscopy and ureteroscopy. Virtual scribes and similar AI tools aim to ...

The AUSCO study assessed the artificial urinary sphincter's impact on incontinence and quality of life in men post-prostate surgery or with other urinary issues. Conducted across 18 sites, the study ...

PSMA-PET imaging enhances precision in radiation therapy for prostate cancer, improving treatment efficacy by accurately targeting cancerous areas. Emory study showed PET-guided radiation ...

The study involved a large international, multi-center cohort of approximately 4,000 patients undergoing inflatable penile prosthesis surgery. No significant differences in intraoperative or ...

Aquablation with the HYDROS System integrates AI, cystoscopic, and ultrasonic imaging for personalized treatment planning in benign prostatic hyperplasia. Understanding transrectal ultrasonography, ...

mCSPC treatment requires personalized approaches, considering disease burden, patient comorbidities, and genetic profiles to optimize outcomes. There is a significant need for more effective ...

ALLO-316 demonstrates significant anti-tumor activity in CD70-positive advanced ccRCC, with a 50% overall response rate in high CD70 expression patients. The therapy maintains a manageable safety ...